Current treatments for Parkinson’s disease target motor symptoms, and do nothing to halt progression or address other aspects of the disease. To get beyond this state of affairs, researchers are targeting the underlying disease pathology. They take guidance from genetic studies that have highlighted the major molecular players, such as α-synuclein, GBA, LRRK2, and tau. At the first Advances in Alzheimer’s and Parkinson’s Therapies focus meeting (AAT-AD/PD), held March 15–18 in Turin, Italy, speakers debated therapies aimed at all of these molecules. Several treatments are in or headed toward the clinic, and most could potentially work for dementia with Lewy bodies (DLB) as well. Researchers agreed the therapies—if they work—mark a sea change for synucleinopathy treatment.
Parkinson’s Treatments Go After Genetic T... - Cure Parkinson's
Parkinson’s Treatments Go After Genetic Targets
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
Stem cell treatment Parkinson’s
Legit Stem Cell therapy for Parkinson’s, particularly young onset
I’d like to know if anyone knows...
Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy? 2021
things will pop out. Tidbits. Clues.
Parkinson’s Disease: Can Targeting Inflammation Be an...
Harnessing Probiotics to Deliver Parkinson’s Disease Treatment
powerful mainstay treatment for Parkinson’s disease. Preclinical tests show that the new treatment...
Studies Show Chinese Herb Effective in Treatment of Parkinson’s
to improve the symptoms associated with Parkinson’s disease.
https://www.theepochtimes.com/health/st
Must Read: Gut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease 24 June 2022
Gut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease...